In particular, venetoclax has shown impressive antitumor efficacies and been approved by US food and drug administration to treat chronic lymphocytic leukemia (CLL), even including those with 17p- or TP53 mutations who belong to the worst prognostic CLL subtype (16). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.